Mauritania vs Morocco: Share of the population living with HIV receiving antiretroviral therapy
Mauritania
75.8%
in 2024
Morocco
76.2%
in 2024
Mauritania rank
64th
Morocco rank
61st
Share of the population living with HIV receiving antiretroviral therapy over time
- Mauritania
- Morocco
How they compare
Morocco currently reports 76.2% against 75.8% in Mauritania, a difference of 0.4%.
The two have swapped places 4 times across 35 shared years of data; in 1990 it was Morocco ahead.
Mauritania ranks 64th and Morocco ranks 61st of 149 countries.
Morocco has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Mauritania | Morocco | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | — |
| 2000s | 4.1% | 6.0% | 1.9% | Morocco |
| 2010s | 31.9% | 34.3% | 2.4% | Morocco |
| 2020s | 64.3% | 68.4% | 4.1% | Morocco |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Mauritania or Morocco?
- Morocco, at 76.2% against 75.8% in Mauritania as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Mauritania and Morocco?
- 0.4%, with Morocco ahead.
- How many years of comparable data are there for Mauritania and Morocco?
- 35 years are reported by both, from 1990 to 2024.
- How do Mauritania and Morocco rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Mauritania ranks 64th and Morocco ranks 61st of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.